This page has been robot translated, sorry for typos if any. Original content here.

Attention! The information is for reference only!
Before taking, be sure to consult a doctor!
SITE ONLY DIRECTORY. NOT A PHARMACY! We do not sell medicines! None!

Description of the medicine: Rifathyroin (Rifathyroinum)

RIFATYROIN (Rifathyroinum).

Pyroglutamyl-histidyl-prolinamide (tripeptide).

Synonyms: Tiroliberin, Hirtonin, Protirelin, Relefact TRH, Thypinone, Thyrefact, Thyroliberin, Tiregan, etc.

White or white with a barely noticeable yellowish tint amorphous powder. Soluble in water and alcohol.

Tiroliberin (rifatiroin) is one of the main releasing factors of the hypothalamus. It promotes the release of thyroid-stimulating hormone of the pituitary gland, i.e. is a releasing factor of thyroid-stimulating hormone. Along with this, tyroliberin has a multifaceted effect on the body. It stimulates the secretion of prolactin, has antidepressant activity.

The main use of thyroliberin (rifatiroin) has as a means of diagnosing various forms of hypothyroidism, as well as the state of the hypothalamic-pituitary thyroid system in various endocrine diseases; it is also used to determine the pituitary reserve of prolactin in women with hypo- and agalactia (lack of milk secretion) and endocrine disorders.

Enter intravenously in a single dose of 500 μg (0.5 mg). Before the introduction and after 15; 30 and 120 minutes after administration, the content of thyroid-stimulating hormone and prolactin in the blood is determined.

After the administration of rifatiroin in 1 - 2 min, nausea, sensation of fever, dizziness, passing independently, are possible.

There is evidence of the use of rifatiroin for the diagnosis of dysfunction of the hypothalamic-pituitary-thyroid system and for monitoring therapy with thyroid drugs by intranasal administration of rifatiroin (application at a dose of 1000 μg in small drops on the mucous membrane of the nasal cavity).

In connection with the psychotropic activity of tyroliberin, its effect on alcohol withdrawal syndrome has been studied with positive results. The drug was administered intravenously at a dose of 200 mcg.

The use of rifatiroin is contraindicated in pregnancy.

Release form: in ampoules containing 500 mcg of dry preparation. Before use, 500 μg is diluted in 2 ml of sterile water for injection or isotonic sodium chloride solution.

Storage: List B. In the dark place at a temperature of +4 C.